Alcon Receives Approvable Letter For EXTRAVAN (TM)
10/19/2005 5:11:29 PM
Alcon, Inc. (NYSE:ACL) today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for EXTRAVAN(TM) ophthalmic solution for the treatment of glaucoma. EXTRAVAN(TM) solution is a fixed combination of travoprost 0.004 percent and timolol 0.5 percent.
comments powered by